Vimarsana
Biggest News Aggregation in the World

Page 10 - Advanced Solid Tumors News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Advanced Solid Tumors. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Advanced Solid Tumors Today - Breaking & Trending Today

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors - Vimarsana News

Dr Luke on Initial Data From the GLIMMER-01 Trial of E-602 in Advanced Solid Tumors

Jason J. Luke, MD, FACP, discusses initial results from the phase 1 GLIMMER-01 trial of E-602 in advanced solid tumors.

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent - Vimarsana News

BASECAMP-1 Aims to Identify Patients Eligible for Treatment With Novel CAR T-Cell Agent

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial, with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in a subsequent trial evaluating the investigational agent A2B530.

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors - Vimarsana News

IO-108 Demonstrates Safety and Efficacy in Advanced Solid Tumors

Findings from a phase 1 study showed that the fully humanized IgG4 antibody IO-108 was well tolerated and displayed durable responses when given as a monotherapy as well as in combination with pembrolizumab, supporting further development of the agent alone or with PD-1/PD-L1 targeted therapy for patients with advanced solid tumors.

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting - Vimarsana News

Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting

New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation SHANGHAI and CAMBRIDGE, Mass., April 11, 2023 -- Zai Lab... | April 11, 2023

BioAtla Reports Fourth Quarter and Full Year 2022 Financial - Vimarsana News

BioAtla Reports Fourth Quarter and Full Year 2022 Financial

- Cleared dose-limiting toxicity (DLT) observation period with more frequent, dose-intensive regimen of CAB-AXL BA3011; anticipated leiomyosarcoma (LMS)...